Trial · NCT00404755
Dichotic Listening as a Predictor of Medication Response in Depression
NCT00404755, Phase 4, Completed, New York State Psychiatric Institute; results first posted 2018-03-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dichotic Listening as a Predictor of Medication Response in Depression. Trials, record NCT00404755. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00404755
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dichotic Listening as a Predictor of Medication Response in Depression
- NCT number
- NCT00404755
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 17 participants, actual
- Lead sponsor
- New York State Psychiatric Institute
- Conditions
- Major Depressive Disorder, Dysthymia
- Interventions
- escitalopram, bupropion, imipramine
- First posted
- 2006-11-29
- Last updated
- 2018-04-30
- Results first posted
- 2018-03-15
- Limitations and caveats
- This is an open (i.e., unblinded) study having small sample size
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hamilton Depression Scale (HAM-D) | 6 weeks or last visit in Phase | Hamilton Depression Scale, 21 item version Summary of all 21 items and higher score means worse depression. Scores range from 0 to a maximum of 63. |
| Secondary | Clinical Global Impression Scale (CGI) | 6 weeks or last visit in Phase | The CGI is a standard measure of global psychopathology. CGI-severity scores rated on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill patients). CGI-improvement scores range from 1 (very much improved) through to 7 (very much worse). |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Hamilton Depression Scale (HAM-D) | 6 weeks or last visit in Phase | Participants were included if they were given that medication | units on a scale | MEAN |
| SECONDARY | Clinical Global Impression Scale (CGI) | 6 weeks or last visit in Phase | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Hamilton Depression Scale (HAM-D) | Bupropion | 11.2 | Standard Deviation 7.9 | units on a scale | |
| Hamilton Depression Scale (HAM-D) | Escitalopram | 9.7 | Standard Deviation 6.4 | units on a scale | |
| Hamilton Depression Scale (HAM-D) | Imipramine | 11.3 | Standard Deviation 8.1 | units on a scale | |
| Clinical Global Impression Scale (CGI) | Bupropion | 2.65 | Standard Deviation 1.12 | units on a scale | |
| Clinical Global Impression Scale (CGI) | Escitalopram | 2.73 | Standard Deviation 1.10 | units on a scale | |
| Clinical Global Impression Scale (CGI) | Imipramine | 2.67 | Standard Deviation 0.58 | units on a scale |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Phase I (Bupropion) | STARTED | Bupropion | 17 | |
| Phase I (Bupropion) | COMPLETED | Bupropion | 13 | |
| Phase I (Bupropion) | NOT COMPLETED | Bupropion | 4 | |
| Phase II (Escitalopram) | STARTED | Bupropion | 11 | |
| Phase II (Escitalopram) | COMPLETED | Bupropion | 9 | |
| Phase II (Escitalopram) | NOT COMPLETED | Bupropion | 2 | |
| Phase III (Imipramine) | STARTED | Bupropion | 3 | |
| Phase III (Imipramine) | COMPLETED | Bupropion | 3 | |
| Phase III (Imipramine) | NOT COMPLETED | Bupropion | 0 |
Source ClinicalTrials.gov
Adverse events33
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Escitalopram | 3 | 11 | 3 |
| other | Nausea | Gastrointestinal disorders | Bupropion | 0 | 17 | 0 |
| other | Nausea | Gastrointestinal disorders | Imipramine | 0 | 3 | 0 |
| other | anorgasmia | Reproductive system and breast disorders | Escitalopram | 5 | 11 | 5 |
| other | anorgasmia | Reproductive system and breast disorders | Bupropion | 0 | 17 | 0 |
| other | anorgasmia | Reproductive system and breast disorders | Imipramine | 0 | 3 | 0 |
| other | headache | General disorders | Escitalopram | 1 | 11 | 1 |
| other | headache | General disorders | Bupropion | 3 | 17 | 3 |
| other | headache | General disorders | Imipramine | 0 | 3 | 0 |
| other | overstimulatioin | General disorders | Escitalopram | 0 | 11 | 0 |
1 to 10 of 33Source ClinicalTrials.gov
See all 33 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Escitalopram | ||
| Total, all-cause mortality | Bupropion | ||
| Total, all-cause mortality | Imipramine | ||
| Total, other adverse events | Escitalopram | 10 | 11 |
| Total, other adverse events | Bupropion | 10 | 17 |
| Total, other adverse events | Imipramine | 3 | 3 |
| Total, serious adverse events | Escitalopram | 0 | 11 |
| Total, serious adverse events | Bupropion | 1 | 17 |
| Total, serious adverse events | Imipramine | 0 | 3 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00404755
GET https://conductscience.org/api/trials/v1/NCT00404755/events?page=2